Research Library
Structure Unavailable
Verified structure not on file
Medicine

Anastrozole

Nonsteroidal aromatase inhibitor; blocks estrogen biosynthesis

Mechanism of Action

Anastrozole is a potent, selective nonsteroidal aromatase inhibitor (type III). It competitively binds to the heme group of cytochrome P450 aromatase (CYP19A1), preventing the conversion of androstenedione and testosterone to estrone and estradiol. This reduces circulating estrogen levels by up to 80% or more. Anastrozole does not affect adrenal steroidogenesis or cortisol/aldosterone production. In research contexts, it is studied for estrogen management during androgen administration and for estrogen-sensitive conditions.

Evidence Chain

Anastrozole

COMPOUND

1 Research Goal

• Sexual Health & Libido

Evidence Strength

Clinical Trial

6 articles sourced

Knowledge Graph

(7 connections)
CompoundGoalArticleArticleArticle
Compound (Center)
Research Goal
Linked Article

Research Evidence

(6)

Clomiphene Citrate: Evidence-Based Research Review

6 min

Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative classified as a Selective Estrogen Receptor Modulator (SERM). Originally developed for the induction of ovulation in women with anovulatory infertility, it has become a cornerstone of reproductive medicine. CC operates as a race

Clinical Trial

Testosterone Enanthate: Evidence-Based Research Review

6 min

Testosterone enanthate (TE) is a long-acting esterified formulation of the primary endogenous androgen, testosterone. Since its clinical introduction in the 1950s, it has served as a cornerstone for testosterone replacement therapy (TRT) in male hypogonadism and a reference compound in clinical rese

Clinical Trial

Raloxifene: Evidence-Based Research Review

6 min

Raloxifene is a second-generation selective estrogen receptor modulator (SERM) of the benzothiophene class. Developed to address the limitations of first-generation SERMs like tamoxifen, raloxifene exhibits distinct tissue-specific effects: it acts as an estrogen receptor (ER) agonist in bone and li

Clinical Trial

BPC-157 and Tissue Repair Signaling Pathways

9 min

Comprehensive review of BPC-157 mechanisms in tissue repair, angiogenesis, and mucosal healing.

Clinical Trial

Boldenone Undecylenate: Evidence-Based Research Review

6 min

Boldenone undecylenate, a synthetic derivative of testosterone originally developed for veterinary use, is a long-acting injectable anabolic-androgenic steroid (AAS). Characterized by a double bond between the C1 and C2 positions, the compound exhibits a favorable ratio of anabolic to androgenic act

Preclinical

Trenbolone Acetate: Evidence-Based Research Review

6 min

Trenbolone acetate (TBA) is a potent synthetic 19-nortestosterone derivative classified as an anabolic-androgenic steroid (AAS). Originally developed for veterinary applications—specifically to increase muscle mass and feed efficiency in beef cattle—TBA has become a focal point of pharmacological in

Preclinical

Synergy & Compatibility

(5)

Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.

Highest Compatibility

Anastrozole + Raloxifene

Moderate Compatibility

60%
View full comparison matrix

Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.

Community Observations

(0)

Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.

No approved observations yet. Sign in to contribute.

Research Use Only

For research use only. Not medical advice.

ARIA · Sign in to chat